Clene Nanomedicine Presents Updated Data From Mid-Stage Amyotrophic Lateral Sclerosis Trials


Clene Inc CLNN has announced multiple presentations of updated clinical trial results from the Phase 2 RESCUE-ALS and REPAIR trials at the 2022 MDA Clinical & Scientific Conference.

  • RESCUE-ALS Phase 2 trial examined the efficacy, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in 45 participants with early ALS over a 36-week treatment period. 
  • Significant benefits were observed with CNM-Au8 treatment, including slowing ALS disease progression and decreasing the proportion of participants with a 6-point decline in the ALS Functional Rating Scale.
  • Related: Clene's Amyotrophic Lateral Sclerosis Candidate Shows Favorable Impact On Disease Progression.
  • The Company also shared the analyses of long-term open-label extension of the RESCUE-ALS trial, indicating improved survival compared to predictions derived from the validated ENCALS risk model.
  • Interim results demonstrate approximately 70% decreased risk of death for participants who entered the RESCUE-ALS long-term open-label extension.
  • Price Action: CLNN shares are down 0.71% at $2.80 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefsPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!